Use of Antithrombotic Agents Among U.S. Stroke Survivors, 2000-2006

American Journal of Preventive Medicine

Volumn 38, Issue 1, 2010, Pages 47-53

  Cheng, Eric M ^a,b   Cohen, Stanley N ^e   Lee, Martin L ^b,c   Vassar, Stefanie D ^a,b   Chen, Alex Y ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Nevada Neurosciences Institute at Sunrise   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRESCRIPTION; STROKE; SURVIVOR;

AGED; FEMALE; FIBRINOLYTIC AGENTS; HEALTH CARE SURVEYS; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; STROKE; SURVIVORS; UNITED STATES;

EID: 72049091998     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2009.08.029     Document Type: Article

References (31)

1. Albers G.W., Easton J.D., Sacco R.L., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 114 5S (1998) S683-S698
2. Wolf P.A., Clagett G.P., Easton J.D., et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 30 9 (1999) 1991-1994
3. Albers G.W., Hart R.G., Lutsep H.L., Newell D.W., and Sacco R.L. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 30 11 (1999) 2502-2511
4. Shahar E., Folsom A.R., Romm F.J., et al. Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 131 5 (1996) 915-922
5. O'Connor P.J., Pronk N.P., Tan A.W., Rush W.A., and Gray R.J. Does professional advice influence aspirin use to prevent heart disease in an HMO population?. Eff Clin Pract 1 1 (1998) 26-32
6. Cook N.R., Chae C., Mueller F.B., Landis S., Saks A.M., and Hennekens C.H. Mis-medication and underutilization of aspirin in the prevention and treatment of cardiovascular disease. Med Gen Med (1999) E1
7. Rolka D.B., Fagot-Campagna A., and Narayan K.M. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 24 2 (2001) 197-201
8. Brown J.B., Delea T.E., Nichols G.A., Edelsberg J., Elmer P.J., and Oster G. Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med 162 2 (2002) 193-199
9. Kim C., and Beckles G.L. Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am J Prev Med 27 1 (2004) 1-7
10. Persell S.D., and Baker D.W. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med 164 22 (2004) 2492-2499
11. Brown D.W., Shepard D., Giles W.H., Greenlund K.J., and Croft J.B. Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. Ethn Dis 15 4 (2005) 620-626
12. Stafford R.S., Monti V., and Ma J. Underutilization of aspirin persists in U.S. ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2 12 (2005) e353
13. Ajani U.A., Ford E.S., Greenland K.J., Giles W.H., and Mokdad A.H. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 30 1 (2006) 74-77
14. Opotowsky A.R., McWilliams J.M., and Cannon C.P. Gender differences in aspirin use among adults with coronary heart disease in the U.S. J Gen Intern Med 22 1 (2007) 55-61
15. Pignone M., Anderson G.K., Binns K., Tilson H.H., and Weisman S.M. Aspirin use among adults aged 40 and older in the U.S.: results of a national survey. Am J Prev Med 32 5 (2007) 403-407
16. Diener P.H.-C., Bogousslavsky P.J., Brass P.L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 9431 (2004) 331-337
17. Cheng E., Chen A., Vassar S., Lee M., Cohen S., and Vickrey B. Comparison of secondary prevention care after myocardial infarction and stroke. Cerebrovasc Dis 21 (2006) 235-241
18. Cohen S.B. Design strategies and innovations in the Medical Expenditure Panel Survey. Med Care 41 7S (2003) III5-III12
19. Cairns J.A., Theroux P., Lewis Jr. H.D., Ezekowitz M., Meade T.W., and Sutton G.C. Antithrombotic agents in coronary artery disease. Chest 114 5S (1998) S611-S633
20. Smith Jr. S.C., Blair S.N., Bonow R.O., et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104 13 (2001) 1577-1579
21. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 4 (2008) e25-e146
22. Muntner P., DeSalvo K.B., Wildman R.P., Raggi P., He J., and Whelton P.K. Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke. Am J Epidemiol 163 10 (2006) 913-920
23. Commitee C.S. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 9038 (1996) 1329-1339
24. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 1-2 (1996) 1-13
25. Schwamm L.H., Fonarow G.C., Reeves M.J., et al. Get with the guidelines-stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 119 (2009) 107-115
26. Caetano P.A., Lam J.M., and Morgan S.G. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 28 9 (2006) 1411-1424
27. Glader E.-L., Stegmayr B., Norrving B., et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 34 8 (2003) 1970-1975
28. Tuhrim S., Cooperman A., Rojas M., et al. The association of race and sex with the underuse of stroke prevention measures. J Stroke Cerebrovasc Dis 17 4 (2008) 226-234
29. Simpson C.R., Wilson C., Hannaford P.C., and Williams D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke 36 8 (2005) 1771-1775
30. Walker M.K., Whincup P.H., Shaper A.G., Lennon L.T., and Thomson A.G. Validation of patient recall of doctor-diagnosed heart attack and stroke: a postal questionnaire and record review comparison. Am J Epidemiol 148 4 (1998) 355-361
31. Okura Y., Urban L.H., Mahoney D.W., Jacobsen S.J., and Rodeheffer R.J. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 57 10 (2004) 1096-1103